Form 8-K - Current report:
SEC Accession No. 0001437749-21-019888
Filing Date
2021-08-13
Accepted
2021-08-13 16:30:48
Documents
15
Period of Report
2021-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20210813_8k.htm   iXBRL 8-K 29212
2 EXHIBIT 99.1 ex_275733.htm EX-99.1 23114
7 logo.jpg GRAPHIC 5950
  Complete submission text file 0001437749-21-019888.txt   199685

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20210811.xsd EX-101.SCH 3593
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20210811_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20210811_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20210811_pre.xml EX-101.PRE 11584
8 EXTRACTED XBRL INSTANCE DOCUMENT dffn20210813_8k_htm.xml XML 2575
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211172613
SIC: 2834 Pharmaceutical Preparations